Literature DB >> 28035697

Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Mario González-Sales1,2, Fahima Nekka1,3, Mario Tanguay2, Pierre-Olivier Tremblay2, Jun Li1,3.   

Abstract

AIMS: The aim of this paper is to investigate the role of drug concentration samplings in the modelling of the dose-response relationship.
METHODS: Using an initial PK/PD model, a reference dataset was simulated. PK and PD samples were extracted to create reduced datasets. PK/PD and K-PD models were fitted to theses reduced datasets. Post hoc estimates from both types of models were compared to the initial PK/PD model and performance was assessed.
RESULTS: K-PD models were largely biased when the drug has a nonlinear elimination. PK/PD models with 1 PK and 2 PD samples were superior to K-PD models with 3 PD samples. PK/PD models with 1 or 2 PK samples and 3 PD samples proved to be superior to K-PD models with 4 PD samples.
CONCLUSIONS: K-PD models should not be used when the drug has nonlinear elimination. K-PD models should not replace PK/PD modelling but are an alternative approach if the PD information is large enough.
© 2016 The British Pharmacological Society.

Entities:  

Keywords:  K-PD; NONMEM®; PK/PD; dose-response relationship

Mesh:

Year:  2017        PMID: 28035697      PMCID: PMC6396849          DOI: 10.1111/bcp.13225

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Modeling of dose-response-time data: four examples of estimating the turnover parameters and generating kinetic functions from response profiles.

Authors:  J Gabrielsson; W J Jusko; L Alari
Journal:  Biopharm Drug Dispos       Date:  2000-03       Impact factor: 1.627

2.  Modeling of pharmacokinetic/pharmacodynamic (PK/PD) relationships: concepts and perspectives.

Authors:  H Derendorf; B Meibohm
Journal:  Pharm Res       Date:  1999-02       Impact factor: 4.200

3.  Evaluation of IPPSE, an alternative method for sequential population PKPD analysis.

Authors:  B D Lacroix; L E Friberg; M O Karlsson
Journal:  J Pharmacokinet Pharmacodyn       Date:  2012-01-21       Impact factor: 2.745

4.  Modelling response time profiles in the absence of drug concentrations: definition and performance evaluation of the K-PD model.

Authors:  P Jacqmin; E Snoeck; E A van Schaick; R Gieschke; P Pillai; J-L Steimer; P Girard
Journal:  J Pharmacokinet Pharmacodyn       Date:  2006-10-19       Impact factor: 2.745

5.  Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Authors:  Mario González-Sales; Fahima Nekka; Mario Tanguay; Pierre-Olivier Tremblay; Jun Li
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

6.  Kinetics of pharmacologic activity of succinylcholine in man.

Authors:  G Levy
Journal:  J Pharm Sci       Date:  1967-12       Impact factor: 3.534

7.  Simultaneous modeling of pharmacokinetics and pharmacodynamics with a nonparametric pharmacodynamic model.

Authors:  E Fuseau; L B Sheiner
Journal:  Clin Pharmacol Ther       Date:  1984-06       Impact factor: 6.875

Review 8.  Pharmacokinetic and pharmacodynamic modeling in vivo.

Authors:  N H Holford; L B Sheiner
Journal:  Crit Rev Bioeng       Date:  1981

9.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

10.  Pharmacodynamic models for the cardiovascular effects of moxonidine in patients with congestive heart failure.

Authors:  L Brynne; J L McNay; H G Schaefer; K Swedberg; C G Wiltse; M O Karlsson
Journal:  Br J Clin Pharmacol       Date:  2001-01       Impact factor: 4.335

View more
  4 in total

1.  Modelling the dose-response relationship: the fair share of pharmacokinetic and pharmacodynamic information.

Authors:  Mario González-Sales; Fahima Nekka; Mario Tanguay; Pierre-Olivier Tremblay; Jun Li
Journal:  Br J Clin Pharmacol       Date:  2017-02-14       Impact factor: 4.335

2.  Correction.

Authors: 
Journal:  Br J Clin Pharmacol       Date:  2018-06-15       Impact factor: 4.335

3.  Kinetic-pharmacodynamic model for drugs with non-linear elimination: Parameterisation matters.

Authors:  Qing Xi Ooi; Chihiro Hasegawa; Stephen B Duffull; Daniel F B Wright
Journal:  Br J Clin Pharmacol       Date:  2020-01-10       Impact factor: 4.335

4.  Model-Based Anticancer Effect of Botulinum Neurotoxin Type A1 on Syngeneic Melanoma Mice.

Authors:  Won-Ho Kang; Hyo-Jeong Ryu; Seongsung Kwak; Hwi-Yeol Yun
Journal:  Front Pharmacol       Date:  2022-01-04       Impact factor: 5.810

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.